Compare VSME & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSME | GRI |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 4.5M |
| IPO Year | 2022 | 2020 |
| Metric | VSME | GRI |
|---|---|---|
| Price | $1.07 | $1.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | 40.7K | ★ 523.3K |
| Earning Date | 10-31-2025 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.07 | $0.18 |
| 52 Week High | $5.38 | $6.70 |
| Indicator | VSME | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 31.65 | 50.35 |
| Support Level | $0.87 | $1.36 |
| Resistance Level | $0.94 | $2.53 |
| Average True Range (ATR) | 0.06 | 0.30 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 0.00 | 16.37 |
VS Media Holdings Ltd manages a network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fan bases on social media platforms. The company's business provides value to two business stakeholders: marketing services and social commerce. The firm generates almost all of its revenue from marketing services, which reflects the company's business of marketing services to clients and social media platforms. The social commerce segment reflects the company's business of social commerce with customers. Geographically, the firm generates revenue from the HK SAR and Taiwan.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.